CYTH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CYTH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cyclo Therapeutics's enterprise value is $26.25 Mil. Cyclo Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-20.03 Mil. Therefore, Cyclo Therapeutics's EV-to-EBITDA for today is -1.31.
The historical rank and industry rank for Cyclo Therapeutics's EV-to-EBITDA or its related term are showing as below:
During the past 13 years, the highest EV-to-EBITDA of Cyclo Therapeutics was 92.71. The lowest was -474.89. And the median was -3.52.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-19), Cyclo Therapeutics's stock price is $1.16. Cyclo Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.310. Therefore, Cyclo Therapeutics's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
The historical data trend for Cyclo Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cyclo Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Cyclo Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cyclo Therapeutics's EV-to-EBITDA falls into.
Cyclo Therapeutics's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | 26.245 | / | -20.031 | |
= | -1.31 |
Cyclo Therapeutics's current Enterprise Value is $26.25 Mil.
Cyclo Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-20.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyclo Therapeutics (NAS:CYTH) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Cyclo Therapeutics's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 1.16 | / | -1.310 | |
= | At Loss |
Cyclo Therapeutics's share price for today is $1.16.
Cyclo Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.310.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of Cyclo Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Vivien Wong | director | 6C CHATEAUX CIRCLE, SCARSDALE NY 10583 |
Rafael Holdings, Inc. | 10 percent owner | 520 BROAD STREET, NEWARK NJ 07120 |
William Conkling | director | C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102 |
Jeffrey Tate | director, officer: Chief Executive Officer | C/O CTD HOLDINGS, INC., 27317 NW 78TH AVENUE, HIGH SPRINGS FL 32643 |
Francis Patrick Ostronic | director | 932 HUNGERFORD DRIVE, SUITE 28A, ROCKVILLE MD 20850 |
Markus Sieger | director | BEUTSTWEG 12, CH-8032, ZURICH V8 000000000 |
N Scott Fine | director | 600 3RD AVE, NEW YORK NY 10016 |
Sharon Hemond Hrynkow | officer: SVP for Medical Affairs | 4816 KING SOLOMON DRIVE, ANNADALE VA 22003 |
Lise Lund Kjems | officer: Chief Medical Officer | 91 ROLLINGWOOD LN., CONCORD MA 01742 |
Joshua M Fine | officer: Chief Financial Officer | 21 HEMMELSKAMP ROAD, WILTON CT 06897 |
Armistice Capital Master Fund Ltd. | 10 percent owner | C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
Michael Eric Lisjak | officer: Chief Regulatory Officer | 12 ROOSEVELT AVENUE, OLD GREENWICH CT 06870 |
Steven Boyd | 10 percent owner | 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
Armistice Capital, Llc | 10 percent owner | 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
L.p. Novit, | 10 percent owner | 966 HUNGERFORD DRIVE, ROCKVILLE MD 20850 |
From GuruFocus
By Business Wire Business Wire • 06-12-2023
By Business Wire • 10-05-2023
By Business Wire Business Wire • 07-21-2022
By Business Wire • 06-29-2023
By Business Wire Business Wire • 01-04-2023
By Business Wire Business Wire • 11-11-2022
By Business Wire Business Wire • 06-21-2022
By Business Wire Business Wire • 01-10-2023
By Business Wire • 08-02-2023
By Business Wire • 11-21-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.